The adjunctive use of glucagon-like peptide 1 receptor agonists (GLP-1 RA) as an addition to insulin is increasingly viewed as a method for addressing the rising prevalence of obesity in type 1 diabetes (T1D). Current GLP-1 RA drugs, such as semaglutide and the dual glucagon-insulinotropic peptide (GIP)/GLP-1 tirzepatide...
.png)
3773 Howard Ave Las Vegas, NV
877-749-7128 ext. 500
Bruce.Oliver@REIPremiumCapitalLender.com
Copyright © 2023 privatemoneybroker. All Rights Reserved
